Insulet Corporation to Present at Upcoming Investor Conferences

BEDFORD, MA--(Marketwire - November 29, 2011) - Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced the Company will participate in the following investor conferences:

• The Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference at the St. Regis in San Francisco. Management is scheduled to present an overview of the Company on Tuesday, December 6 at 2:40 p.m. PT.

• The Oppenheimer 22nd Annual Healthcare Conference at the Waldorf Astoria in New York City. Management is scheduled to present an overview of the Company on Tuesday, December 13 at 4:30 p.m. ET.

During the presentations, material information concerning the Company, its operations, strategies and prospects may be discussed. To listen to audio webcasts of the presentations during the event, please visit: http://investors.insulet.com. A replay of each webcast will be available for 10 days after the initial presentation.

About Insulet Corporation
Insulet Corporation is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and fully-automated cannula insertion. Founded in 2000, Insulet Corporation is based in Bedford, Mass. For more information, please visit: http://www.myomnipod.com.